ChatGPT Enterprise Accelerates Life-Saving Drug Development for Global Biopharmaceutical Leader

Moderna, a global biopharmaceutical company, is on a mission to develop life-saving mRNA medicines. Faced with the challenge of scaling innovation across every business function—from research and manufacturing to legal and commercial operations—Moderna needed a technology-forward approach that could amplify human capacity without proportional increases in workforce. In early 2023, Moderna began its partnership with OpenAI, first adopting their API to build mChat, an internal AI tool that achieved 80% employee adoption. This success laid the foundation for deploying ChatGPT Enterprise across the entire organization, with Moderna's leadership committing to 100% adoption and proficiency within six months.

Moderna implemented a comprehensive change management strategy combining individual, collective, and structural initiatives to ensure widespread adoption. The company invested in in-person and online trainings, established 2,000 active weekly participants in an internal AI forum, and identified the top 100 power users as Generative AI Champions. Within two months of ChatGPT Enterprise deployment, the results exceeded expectations: Moderna created 750 custom GPTs across departments, with 40% of weekly active users developing their own GPTs, and employees averaging 120 ChatGPT Enterprise conversations per week. The legal team achieved 100% adoption, deploying specialized GPTs like Contract Companion for rapid document review and Policy Bot for internal compliance queries. The corporate brand team built GPTs to summarize quarterly earnings calls and translate complex biotech terminology for investor and patient communications.

Moderna is leveraging ChatGPT Enterprise to accelerate its most critical mission: delivering life-saving treatments at scale. The clinical development team deployed Dose ID, a GPT powered by advanced data analysis capabilities, to review clinical data, create visualizations, and support dose selection for vaccine trials—enhancing both accuracy and safety while reducing analysis time. By improving business processes across research, manufacturing, and commercial functions, Moderna believes it can maximize patient impact by leveraging AI and technology to enable a lean workforce to operate at the scale of a much larger organization, while advancing its goal to bring 15 new products to market within five years.